Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels.
about
Statin therapy in metabolic syndrome and hypertension post-JUPITER: what is the value of CRP?Debate: Statins should be used in patients with heart failureThe effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia.Statins and cancersThe stats are in: an update on statin use in COPDRole of C-reactive protein in cardiovascular diseaseC-reactive protein (CRP)-lowering agentsOngoing clinical trials of the pleiotropic effects of statinsCritical appraisal of C-reactive protein throughout the spectrum of cardiovascular diseaseAtorvastatin at reperfusion reduces myocardial infarct size in mice by activating eNOS in bone marrow-derived cells.Overview of the metabolic syndrome; an emerging pandemic of public health significance.Influenza morbidity and mortality in elderly patients receiving statins: a cohort study.Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT)Effects of C-reactive Protein and Homocysteine on Cytokine Production: Modulation by Pravastatin.High-sensitivity C-reactive protein and interleukin-6-dominant inflammation and ischemic stroke risk: the northern Manhattan study.Statins Decrease Oxidative Stress and ICD Therapies.Novel markers of peripheral arterial disease.Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength?Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose toleranceEffects of aspirin & simvastatin and aspirin, simvastatin, & lipoic acid on heme oxygenase-1 in healthy human subjects.Neutrophil/Lymphocyte ratio is associated with non-calcified plaque burden in patients with coronary artery diseaseThe use of statins in acute coronary syndromes: the mechanisms behind the outcomes.Ambient particulate matter, C-reactive protein, and coronary artery disease.Risk stratification in non-ST segment elevation acute coronary syndromes with special focus on recent guidelines.Cardiac protection by pharmacological modulation of inflammation.Statins and inflammatory markers.Vascular inflammation as a therapeutic target for prevention of cardiovascular disease.Atherosclerosis and inflammation.How can the cardiac death rate be reduced in dialysis patients?Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis?Lipoprotein(a) Is the Best Single Marker in Assessing Unstable Angina Pectoris.Matrix metalloproteinases and atherosclerotic plaque instability.Simvastatin for the prevention of exacerbations in moderate-to-severe COPDEarly use of statins in acute coronary syndromes.Lipid-lowering therapies in the management of acute coronary syndromes.Effects of high versus low-dose atorvastatin on high sensitive C-reactive protein in acute coronary syndromePharmacology of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin.DHA supplementation decreases serum C-reactive protein and other markers of inflammation in hypertriglyceridemic menInflammatory bio-markers and cardiovascular risk prediction.High sensitivity C-reactive protein: an emerging role in cardiovascular risk assessment.
P2860
Q24602803-6741759A-07E3-4BFC-8D11-2920130E6E5AQ24799320-D8A8F809-B047-4388-B657-988107916881Q24811721-A459F054-B157-4AF3-8716-A66EB015B642Q26777793-4DCB05C0-69DE-4BB8-BED3-7CA0C85C0465Q26778906-53F6C522-3082-4C5D-98FC-D27D01104C96Q28166927-85C9AD84-401B-4D77-9ED4-28A13A0D4372Q28200344-1489F6B2-48D6-42D4-AD90-D7BF8B13E8B4Q28219321-79259652-2D42-4B0A-9E20-20BA8A1A0789Q28219483-40262189-B014-4175-B7F4-31E51667CA10Q30301174-F2062A47-205E-48B8-8FF0-996C12FBF206Q30366107-CAB23CB0-4D17-4986-AFDA-3C9E575DE605Q30383137-73CE158C-5944-40B1-98BE-C29DE0644D96Q33556796-B7A4BE96-19E7-49DC-AEBC-2802F35AC3F8Q33633640-949846A0-97AC-4669-A762-4EB47BC73832Q33723646-C569B611-1B68-4030-9822-65F2AE278967Q33760881-01E40ADE-531F-4825-AD02-E69D7F55125CQ33984026-4F840768-B314-4338-815E-511BEF87BCF4Q34023548-82DD0796-8A8B-410F-82B4-432AE07EA69FQ34225645-2C2A4DAB-1460-4BAC-AABE-E43DC010FEE7Q34255336-A8EB8CA5-6031-4E74-934E-36248CCECD69Q34277169-C6129BA1-6A72-4255-975E-749339190DC6Q34327214-6628D138-04B7-4B8F-B6C8-E5B88924D75FQ34434076-6F438314-5A2D-4F51-834D-4F52DCA73620Q34445660-AA9D7DC0-C949-4A61-8DCF-901A0B02ED68Q34481804-63A253D9-D39C-4416-8CF0-4F9D43C3ECEAQ34482145-ED825A42-94B7-4A76-B23C-457D7090E3B9Q34514026-D3ABEDB5-C36F-40B1-9629-C177074E880FQ34514032-0765FA7D-A2ED-4922-8F8F-0C2AE9B54098Q34549918-C71602B4-4102-45F8-BA8B-65E46519A7D0Q34601733-C2EA3F4D-2125-433C-A393-841F19420A64Q34635132-0AB3D79D-0EB1-4529-BA6E-DD1770217A02Q34655385-ADD9BB92-D01B-4D6D-BF4E-B29A5B26B6B8Q34661935-298D4849-0950-4A6E-96EA-01A172783351Q34674169-467EDA8F-EC84-4FD8-A019-D316F4DF9037Q34674174-538ABDC7-ED5A-476A-AF6A-BA5819F775EFQ34675610-B563BC0A-E70C-4917-9F95-83664C8B8294Q34773911-BBAA5992-29E4-4407-839B-0B1D1AEB9CA0Q34926392-2FE330CE-0FDB-480F-8C84-4798151E78C1Q34941391-BC63D636-2ED2-45D3-AD93-F77B384DB70FQ34973446-E3853E31-344A-49AD-B565-144366B787D4
P2860
Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels.
description
2001 nî lūn-bûn
@nan
2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Effect of hydroxymethyl glutar ...... ive C-reactive protein levels.
@ast
Effect of hydroxymethyl glutar ...... ive C-reactive protein levels.
@en
type
label
Effect of hydroxymethyl glutar ...... ive C-reactive protein levels.
@ast
Effect of hydroxymethyl glutar ...... ive C-reactive protein levels.
@en
prefLabel
Effect of hydroxymethyl glutar ...... ive C-reactive protein levels.
@ast
Effect of hydroxymethyl glutar ...... ive C-reactive protein levels.
@en
P2093
P1433
P1476
Effect of hydroxymethyl glutar ...... ive C-reactive protein levels.
@en
P2093
P304
P356
10.1161/01.CIR.103.15.1933
P407
P577
2001-04-01T00:00:00Z